Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 12, 2007, Pages 1825-1829

  Mandal, Subrata ^a   Venkatesh, Pradeep ^a   Abbas, Zahir ^a   Vohra, Rajpal ^a   Garg, Satpal ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bevacizumab; Idiopathic juxtafoveal telangiectasia (IJT); Subretinal neovascularization

Indexed keywords

BEVACIZUMAB; GATIFLOXACIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CASE STUDY; CATARACT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA TEAR; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; TELANGIECTASIA; THROMBOEMBOLISM; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; TELANGIECTASIS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 35548994347     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0567-8     Document Type: Article

References (14)

1. Gass JD, Oyakawa RT (1982) Idiopathic juxtafoveal retinal telangiectasis. Arch Ophthalmol 100:769-780
2. Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536-1546
3. Gass JDM (1997) Retinal capillary diseases. In: Stereoscopic atlas of macular diseases, 4th edn. Mosby, St Louis, pp 506-510
4. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812-819
5. Engelbrecht NE, Aaberg TM, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120:320-324
6. Berger AS, McCuen BW II, Brown GC, Brownlow RL Jr (1997) Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 17:94-98
7. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372
8. Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1-9
9. Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91(2):157-160
10. Sakaguchi H, Ikuno Y, Gomi F et al (2007) Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 91(2):161-165
11. Potter MJ, Szabo SM, Chan EY, Morris AH (2002) Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 133:149-151
12. Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 53:61-63
13. Smithen LM, Spaide RF (1997) Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Retina 17:94-98
14. Jorge R, Costa RA, Calucci D, Scott IU (2006) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol, Nov 29 (Epub ahead of print)